Tezepelumab granted Priority Review by U.S. FDA
The Pharma Data
JULY 8, 2021
“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. .” Amgen (NASDAQ:AMGN) announced that the U.S. Reese, M.D., About Severe Asthma.
52 
Let's personalize your content